Mary Kay Fenton - 31 Dec 2025 Form 4 Insider Report for Cullinan Therapeutics, Inc. (CGEM)

Role: Chief Financial Officer
Signature: /s/ Jacquelyn Sumer, Attorney-in-Fact
Issuer symbol: CGEM
Transactions as of: 31 Dec 2025
Net transactions value: +$175
Form type: 4
Filing time: 05 Jan 2026, 17:01:30 UTC
Previous filing: 21 Feb 2025
Next filing: 19 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Fenton Mary Kay	Chief Financial Officer	C/O CULLINAN THERAPEUTICS, INC., ONE MAIN STREET, SUITE 1350, CAMBRIDGE	/s/ Jacquelyn Sumer, Attorney-in-Fact	05 Jan 2026	0001378589

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CGEM	Common Stock	Award	$175	+27	+0.04%	$6.49	62,028	31 Dec 2025	Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of July 1, 2025 through December 31, 2025. This transaction is also exempt under Rule 16b-3(c).
F2	In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on July 1, 2025.
F3	Includes 2,001 shares of common stock that the Reporting Person purchased pursuant to the Issuer's 2021 Employee Stock Purchase Plan for the purchase period of January 1, 2025 through June 30, 2025 that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).